⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803640 | 1.00 | — | — | |
| SCHEMBL407037 | 1.00 | — | — | |
| SCHEMBL21625547 | 0.81 | SLC1A3 (0.38) | — | |
| SCHEMBL3901335 | 0.81 | TDP1 (0.50) | — | |
| SCHEMBL4948304 | 0.80 | SLC1A3 (0.39) | — | |
| SCHEMBL8384843 | 0.80 | — | — | |
| SCHEMBL188173 | 0.78 | SLC1A3 (0.48) | — | |
| Bicarbonate SCHEMBL38662559 | 0.78 | OR51E2 (0.43) | — | |
| SCHEMBL2738309 | 0.78 | SLC1A3 (0.48) | — | |
| SCHEMBL27681307 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230339851-A1 | CXCR6 SULFONAMIDE COMPOUNDS | CHEMOCENTRYX, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115894606-A | RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4054719-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114786777-A | RAS inhibitors | 锐新医药公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-8476256-B2 | Diazonamide analogs | JOYANT PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120196907-A1 | Diazonamide Analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-08-02 | — | — | US | disclosed |
| US-20120196907-A1 | Diazonamide Analogs | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-08-02 | — | — | US | disclosed |
| US-8153619-B2 | Diazonamide analogs | JOYANT PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100022607-A1 | DIAZONAMIDE ANALOGS | JOYANT PHARMACEUTICALS, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2003104200-A1 | N-MERCAPTOACYL PHENYALANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-12-18 | — | — | WO | disclosed |
| US-4734367-A | OPTICALLY ACTIVE INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1988-03-29 | — | — | US | disclosed |